marked.bio

Company

Rigel Pharmaceuticals

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

olutasidenib 1pralsetinib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

    Recruiting Phase 4 Rigel Pharmaceuticals Started 2026Primary completion 2027-04 NCT07486713

    olutasidenib FDACYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates

    Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

    IDH1/2 mutationAML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies

  2. Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

    Recruiting Phase 4 Rigel Pharmaceuticals Started 2026Primary completion 2027-07 NCT07704658

    pralsetinib FDACYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive

    … has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.

    RET fusion or mutationNSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies